Role of procalcitonin in guiding antibiotic therapy in acute pancreatitis: A randomised controlled trial
In brief
Procalcitonin guidance does not significantly cut antibiotic use in acute pancreatitis
In this single-center trial, 152 adults with acute pancreatitis had the same median antibiotic use with procalcitonin guidance as with standard care: 7 defined daily doses in each group. Fewer patients received antibiotics with guidance, but the difference was not statistically significant, and clinical outcomes were similar. Larger multicenter trials are needed to establish whether the approach benefits higher-risk patients.
- Journal
- Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (Q1)
- Published
- 3 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Perumal Chakravarthy, Rajendran Theakarajan, Raj Kumar Nagarajan, Apurba Sankar Sastry
- PMID
- 43020742
- DOI
- 10.1016/j.pan.2026.11.001
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 15 November 2026): Randomized trial tests antibiotic stewardship in acute pancreatitis
Abstract
BACKGROUND: Antibiotics are frequently overused in acute pancreatitis despite guideline recommendations against routine prophylactic therapy. Procalcitonin (PCT)-guided antibiotic stewardship may reduce unnecessary antibiotic exposure without compromising clinical outcomes. This study evaluated the efficacy of a PCT-guided algorithm in patients with acute pancreatitis. METHODS: This prospective, single-centre, patient-blinded randomized controlled trial enrolled adults with acute pancreatitis. Patients were randomized (1:1) to receive either PCT-guided antibiotic therapy (PCT arm) or standard guideline-based management (non-PCT arm). Antibiotics in the intervention group were initiated and discontinued according to serial serum PCT measurements using a threshold of 1 ng/mL. The primary outcome was antibiotic usage measured as defined daily dose (DDD). RESULTS: Of 152 randomized patients, 144 completed follow-up (73 non-PCT and 71 PCT). Baseline characteristics were comparable between groups. Median antibiotic usage was similar between the non-PCT and PCT groups (DDD: 7 [5-10] vs. 7 [4-10]; p = 0.872). Fewer patients received antibiotics in the PCT arm (36.6% vs. 45.2%; p = 0.295). Median antibiotic duration was 7 versus 5 days (p = 0.178), while median hospital stay was 6 days in both groups (p = 0.178). Mortality (5.6% vs. 8.2%), infected necrotic collections (7.0% vs. 6.8%), and multidrug-resistant bacteremia (1.4% vs. 1.3%) were comparable. Among patients with mild pancreatitis, antibiotic use was lower with PCT guidance (7.9% vs. 18.4%; p = 0.098). CONCLUSIONS: In this single-centre randomized trial, PCT-guided antibiotic therapy did not result in a statistically significant reduction in antibiotic consumption compared with standard care. Larger, appropriately powered multicentre trials, particularly among patients at risk of infected pancreatic necrosis, are required to determine whether PCT-guided therapy has a clinically meaningful role in antibiotic stewardship.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.